StockData

Roivant Sciences vs Xenon Pharmaceuticals

ROIV and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ROIV and XENE compare

Roivant Sciences is the larger company, worth 7.4 times as much as Xenon Pharmaceuticals ($28.0B against $3.8B).

Roivant Sciences grew revenue faster over the last twelve months (−67.6% versus −100% for Xenon Pharmaceuticals).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricROIVXENE
Size and price
Market cap$28.0B$3.8B
Share price$38.71$38.78
Change, 1 year90.8%−4.9%
Change, 5 years453%41.3%
Beta (5Y)0.420.26
Employees721370
StockData Score
Total score77
Valuation score00
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/S3712×–
P/B6.6×3.0× (better)
FCF yield−2.9% (better)−9.0%
Growth
Revenue growth (TTM)−67.6% (better)−100%
Revenue growth, 5Y average−19.1% (better)−25.3%
Profitability
Operating margin−7915%–
Net margin−3535%–
FCF margin−10901%–
Return on equity−6.2% (better)−43.6%
Return on invested capital−407%−152% (better)
Financial health
Debt / equity0.000.00
Current ratio16.7221.02 (better)
Altman Z-score44.02 (better)40.35
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions78.1%104%
Held by insiders13.9%0.17%
Insider net buying, 12 months−$798M−$20.3M (better)
Superinvestors holding11
Short interest, % of float7.3%7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.